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INTRODUCTION
Endothelial glycocalyx produced by endothelial 
cells occupies a very important position on the 
endothelial surface of blood vessels that inter-
act with plasma proteins and lipids. Endothelial 
glycocalyx is not only present on the surface of 
endothelial cells, but also in the space between 
endothelial cells and on the side of endothelial 
cells that are close to the basement membrane. 
The space between endothelial cells is called 
"endothelial clefts” (ETC) where glycocyte plays 
an important role in the regulation of vascular 
permeability.1–3
Endothelial glycocalyx is composed of glyco-
proteins or proteoglycans as their backbone. 
Proteoglycans and glycoproteins attached to the 
endothelial by various types of bonds. On the lumi-
nal side, they bind to carbohydrates called glycos-
aminoglycans (GAG), which are negatively charged. 
The combination of GAG along with glycoproteins/
proteoglycans forms a complex sequence.2
The thickness of glycocalyx reaches 400-500 nm, 
which exceeds the length of endothelial cell recep-
tors involved in leukocyte attachment to selectins 
and integrins. Studies of the integrin β2 receptor 
lengths are 20 nm and 30 nm for selectin E and 
P.  Endothelial glycocalyx thickness decreases 
according to the diameter of the blood vessels and 
reaches a thickness of 0.2 μm on the microvascular. 
In addition to electron microscopy, the endothelial 
glycocalcular thickness can also be measured using 
orthogonal polarization spectral imaging. By using 
indocyanine green, the endothelial glycocalyx 
volume in humans is estimated to be 700 ml, with 
an outer surface estimated at 350 m2.4
Dynamic balance occurs between dissolved 
components of glycocalyx and blood flow, which 
affect the composition and thickness of the glycoca-
lyx. The interaction between endothelial glycocalyx 
and substances dissolved in plasma will determine 
the biosynthesis and release of the glycocalyx 
components.
PROTEOGLYCANS
Proteoglycans are proteins that make up endo-
thelial glycocalyx which is the backbone of endo-
thelial glycocalyx and bind one or more GAGs. 
Glycosaminoglycans that are bound to proteogly-
cans vary and can change depending on the stimu-
lus given by substances contained in the plasma.2,5,6
Proteoglycans are composed by core proteins 
which consist of syndecan, which attach to the 
endothelial through the membrane-spanning, 
while glypican attaches to the surface of the vascu-
lar endothelial through the GPI anchor. Perlecan, 
versican, biglycan, decorin, and mimecan are 
proteoglycans which after being formed and 
undergo modification in the GAG, the blood vessel 
lumen will be secreted. Each proteoglycan molecule 
can bind GAG that is different depending on the 
stimulus received by cells.2,5,6
Syndecan is the most glycoprotein composed 
of endothelial glycocalyx with molecular weights 
ranging between 19-35 kDa. Research on the 
umbilical vein endothelial found that syndecan-1 
was expressed the most, followed by syndecan-2, 
syndecan-3, syndecan-4, and glypican-1.7 
Glycosaminoglycans are bound to the sides of 
the core protein consisting of heparan sulfate (HS), 
chondroitin sulfate, dermatan sulfate, hyaluronan, 
and keratan sulfate. Heparan sulfate is the highest 
GAG in endothelial glycocalyx, ranges from 50 to 
90%, and has a ratio of 4:1 to chondroitin sulfate, 
the second largest GAG.8 
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ABSTRACT
The surface of endothelial cells is filled with various membrane-bound 
molecules that form the glycocalyx. The endothelial glycocalyx is a 
surface layer mainly consisted of glycosaminoglycans that include 
heparan sulfate, chondroitin sulfate, and hyaluronic acid and its 
core proteins. Previous studies suggest that endothelial surface 
glycocalyx shedding could play a role in endothelial dysfunction and 
inflammation. This article will review the endothelial glycocalyx and 
its role in sepsis. 
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Glycosaminoglycans, such as heparan sulfate 
and chondroitin sulfate contain different sulfat-
ing sequences, sulfuric diversity and to specific 
sulfates that cause glycocalyx to bind various 
molecules. Some of the molecules capable of being 
bound by glycocytes are antithrombin III, hepa-
rin cofactor II, tissue factor pathway inhibitors, 
thrombin, protein C inhibitors. Another molecule 
that is able to be bound is superoxide dismutase 
(SOD), L and P selectin, TGF β, lipoprotein lipase, 
hepatic lipase, fibronectin, and collagen type I, III, 
and V.9 
ENDOTHELIAL GLYCOCALYX 
FUNCTION
Maintaining permeability
The concept of endothelial glycocalyx as a regulator 
of permeability was first put forward by Danielli in 
1940, who stated that there are non-cellular layers 
on the endothelial surface called the endocapillary 
layer. This layer turns out to have a very import-
ant role to maintain and regulate blood vessel 
permeability.1 
Research by Rehm and colleagues on the guinea 
pig coronary arteries proves that endothelial 
glycocalyx has a role in maintaining and limiting 
the transfer of fluid from intravascular to intersti-
tial.10 Research on the mesenteric arteries of mice 
also proved that the glycocalyx layer plays a role in 
determining vascular permeability.2,11
The endothelial glycocalyx structure that 
contains many of the GAG chains that are over-
lapped, results in glycocalyx having a negative 
charge. This negative charge on the surface causes 
the glycocalyx to be able to regulate vascular 
permeability by limiting the entry of certain 
molecules based on the electric charge of the 
molecule. Glycocyte will reject negatively charged 
cells/molecules such as erythrocytes, leukocytes, 
and platelets.2,5,6 Ueda proved that neutralizing 
the charge from endothelial glycocalyx will cause 
an increase in vessel permeability, resulting in 
increased albumin uptake by endothelial cell 
cultures.2,12
Disruption of endothelial glycocalyx causes a 
loss of glycocalyx function to maintain vascular 
permeability, which in turn may lead to edema.6 
This can be proven from studies in mice, where the 
destruction of mice myocardial endothelial glycoc-
alyx causing myocardial edema.13 
Preventing leukocytes and thrombocyte 
attachments with endothelial
Endothelial glycocalyx also functions as a 
barrier to platelet and leukocyte adhesion in the 
vascular wall. There are two mechanisms that 
prevent adhesion of blood cells to the endothelial 
membrane. The first mechanism is the negative 
charge of endothelial glycocalyx which rejects the 
blood cell to attach to the glycocalyx surface. The 
second mechanism is the thickness from glycoca-
lyx endothelial. 
Endothelial glycocalyx thickness exceeds the 
dimensions of cellular adhesion molecules such 
as intercellular adhesion molecule 1 (ICAM-1), 
vascular cell adhesion molecule 1 (VCAM-1), and 
L-selectins, thus preventing blood cell interactions 
with this molecule. Under normal conditions, 
leukocytes are protected from contact with adhe-
sion molecules because of the presence of endo-
thelial glycocalyx. Exposure to pro-inflammatory 
mediators such as IL-1, IL-2, IL-6, TNF-α, and other 
molecules released during acute inflammation such 
as bradykinin, thrombin, VEGF, and histamine.14 
Inflammation causes damage and detachment 
of endothelial glycocalyx, which in turn causes 
leukocytes to be easily exposed to adhesion mole-
cules, resulting in the attachment of leukocytes to 
blood vessel membranes.6 The adhesion molecules 
then stimulate leukocyte rotation, adherence, and 
migration causing inflammation of the endothelial 
lining and tissues. 
Damage to the endothelial subsequently causes 
more severe glycocalyx degradation and shedding 
followed by a progressive increase in paracellular 
permeability. During this shedding process, adhe-
sion molecules are released and can be found in 
the blood circulation. Thus, in patients with sepsis, 
circulating levels of VCAM-1 and ICAM-1 are 
parallel to IL-6.14 
The above theory was proven by research in the 
cremaster venules of mice that had been damaged 
by heparitinase, which causes an increased leuko-
cyte attached to the endothelial. The higher the 
level of heparitinase given, the higher the leukocyte 
attached to the endothelial. The administration 
of ox-LDL (oxidized low-density lipoprotein) 
or TNF-α also causes endothelial glycocalcular 
smoothness which results in increased rolling and 
endothelial leukocyte adhesion.2 Other studies 
showed an increase in leukocyte attachment to the 
cremaster venule endothelial after administration 
of ox-LDL.15 Leukocytes, platelet, and endothelial 
interactions are also increased after the destruction 
of endothelial glycocalyx by ox-LDL.16
Mechanotransduction
The glycocalyx structure delivers the mechanical 
and biochemical forces that pass through the glyco-
calyx into biochemical signals. Fluid shear stress 
(FSS) due to increased flow/blood flow will cause 
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increased production of local nitric oxide (NO), 
which causes vasodilation and increased vascular 
permeability. Vasodilation after FSS is a mechanism 
for protecting blood vessels against stress. Damage 
to endothelial glycocalyx disturbs the mechanism 
of vasodilation induced by NO. Vink et al. proved 
that the damage of endothelial glycocalyx after 
exposure to oxidized lipoproteins causes a loss of 
endothelial ability to produce NO, so vasodilatation 
does not occur after the flow went through these 
veins.17 
The main evidence supporting the role of large 
endothelial glycocalyx in mechanotransduction 
comes from experiments using selective enzymes to 
degrade specific components of endothelial glycoc-
alyx, followed by a reassessment of the glycocalyx 
function after being given FSS.18–20
Research to prove the association between 
FSS, endothelial glycocalyx and cytoskeleton 
rearrangement due to FSS found that endothelial 
glycocalyx is an FSS transduction tool, and there 
is an FSS threshold that triggers the cytoskeleton 
rearrangement. Observations on intact endothe-
lial glycocalyx have severe disturbances in thick 
peripheral actin bands (dense peripheral actin 
band, DPAB), stress fiber formation, and vincu-
lin migration to the cell edge after FSS exposure. 
Although this has been seen in many previous 
studies, this rearrangement disappears completely 
when the integrity of endothelial glycocalyx is 
impaired. 
Protection of endothelial cell
Glycocalyx also acts to protect endothelial cells 
from various damage due to various mediators such 
as oxidative stress. Under normal circumstances, 
glycocalyx store various antioxidants such as SOD 
(superoxide dismutase) which is bound to hepa-
ran sulfate. SOD serves to reduce oxidative stress 
by eliminating/extinguishing the effects of oxygen 
radicals and maintaining bioavailability of NO so it 
can prevent endothelial dysfunction.6
Reducing inflammatory effects
Endothelial glycocalyx is thought to play an 
important role in protecting endothelial cells from 
damage caused by various mediators of oxidative 
stress. Under physiological conditions, endothelial 
glycocalyx contributes to the vasculoprotective 
effect because its capacity binds to superoxide 
dismutase (SOD) enzymes. Extracellular superox-
ide dismutase is bound to heparan sulfate proteo-
glycans, which plays a role in reducing oxidative 
stress by extinguishing oxygen radicals and main-
taining NO bioavailability.6
Dilatation of blood vessels due to FSS followed 
by the release of NO is also a protection system of 
blood vessels because dilation of blood vessels will 
reduce stress on the endothelium.21 Research on the 
human umbilical vein shows that elevated FSS will 
increase the production of hyaluronic acid in glyco-
calyx which also functions to protect blood vessels.1 
Endothelial glycocalyx can also bind to cytokines, 
which have a major influence on composition and 
synthesis or even modulate inflammatory responses 
by increasing the bond between cytokines and 
receptors on the cell surface.6,22,23
GLYCOCALYX ENDOTHELIUM IN SEPSIS
Vascular endothelium is first affected in the 
systemic or local inflammatory processes, either 
due to infection, diabetes mellitus, surgery, isch-
emic reperfusion injury, and atherosclerosis.3,24,25 
As explained earlier, optimal endothelial glycocalyx 
function is highly dependent on intact structures. 
Structural damage can be minor to severe damage. 
Loss of glycocalyx constituents is called shedding.3,25
Shedding of endothelial glycocalyx is found in 
arterioles, capillaries, and venules. It is a result of the 
release of various inflammatory mediators in sepsis, 
such as cytokines and chemoattractant, shown in 
various inflammatory model experiments.3,25,26 
At the beginning of the process of decreasing the 
endothelial glycocalyx layer, the supply of nutrients 
will improve, but microvascular changes due to the 
release of glycocalyx cause reduced blood vessel 
protection which adversely affects the function of 
the blood vessels.27 Endothelial glycocalyx degrada-
tion increase leukocyte access to attach to endothe-
lial adhesion molecules.24
The release of inflammatory mediators in sepsis 
will directly damage the structure of endothelial 
glycocalyx which certainly interferes with endothe-
lial function. Inflammatory reactions also activate 
a subset of leukocytes such as polymorphonuclear 
(PMN), macrophages, and mast cells, to release 
various enzymes that contribute to endothelial 
glycocalyx degradation.27 
TNF-α released during sepsis causes damage 
to the glycocalyx through proteases, which cause 
shedding of GAG, and in more severe circum-
stances, causes the release of core proteins 
(syndecan).23,24,28 TNF-α causes acute shedding of 
coronary arteries and followed by the occurrence 
of myocardial edema which indicated an increase 
in vascular permeability. TNF-α will activate mast 
cells to release cytokines, proteases, and also hepa-
ranase. Heparanase causes heparan sulfate degra-
dation. TNF-α also stimulates nitric oxide synthase 
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to produce NO which causes extensive vasodila-
tion, hypotension, and hyporeactivity to adren-
ergic agents.24 n the study using the sepsis model, 
high TNF-α levels were associated with reduced 
syndecan expression and changes in hyaluronan 
and sialic acid.14 
Research conducted on cremaster’s microvessel 
of rats shows that reactive oxygen species (ROS) 
is also an agent that causes endothelial glycocalyx 
damage. Ischemic injury, reperfusion, and acti-
vated neutrophils cause increased production of 
ROS followed by increased penetration of dextran 
70-kDa, but this condition will improve after super-
oxide dismutase (SOD) is given. This evidence 
shows that ischemic injury and reperfusion cause 
the release of ROS, which can be proven by a reduced 
adverse effect of ROS after SOD administration. 
This study also found that xanthine-oxidoreductase 
(XOR) can increase the production of ROS, which 
can be inhibited by allopurinol so that the effects 
of reperfusion ischemic injury will decrease after 
administration of allopurinol.29 At the time of isch-
emic injury and reperfusion, XOR will be released 
in very large amounts into the circulation, due to 
cell damage. Circulating XOR undergoes proteoly-
sis with the help of enzyme serine protease to XO, 
which is then immobilized/binds to the glycocalyx 
endothelium.
Some studies have successfully evaluated 
syndecan-1 and GAG in septic patients.30,31 
Circulation levels of syndecan-1 are associated with 
endothelial damage and endothelial glycocalyx 
degradation. If there is degradation of endothelial 
glycocalyx, there will be shedding of fragments 
such as syndecan-1 into the blood circulation. 
A cross-sectional study reported a significantly 
higher syndecan-1 level in the septic shock group 
compared to controls (246 ng/mL (140-496) vs. 
23 ng/mL (26-31), p <0.001). This study also found 
high GAG levels in septic shock patients compared 
to controls, and GAG levels were significantly 
higher in patients who died. In the same study, the 
syndecan-1 level also increased and turned out to 
be positively correlated with the Sequential Organ 
Failure Assessment score (SOFA) scores.30
The study of 150 subjects suffering from severe 
sepsis, septic shock, and post-digestive surgery 
with no systemic inflammatory response syndrome 
(SIRS) compared to healthy subjects showed a 
significant increase in syndecan-1 and heparan 
sulfate levels in the ill-subjects compared to the 
healthy subjects. The highest increase in syndecan-1 
levels was obtained in the sepsis and postoperative 
groups. The high levels of syndecan-1 in sepsis 
patients turned out to be positively correlated with 
IL-6 levels.32 Sallisami et  al. reported a significant 
increase in the level of syndecan-1 in the septic shock 
group compared to the control group (p <0.01). The 
study also reported a positive correlation between 
VICAM-1 and the first-day SOFA scores.33 
Other study reported that the syndecan-1 levels 
were positively correlated with the severity of sepsis 
based on the score of Acute Physiology and Chronic 
Health Evaluation (APACHE) II (r = 0.425, p = 0.001), 
SOFA score (r = 0.476, p = 0.003), and Multiple Organ 
Dysfunction Syndrome (MODS) (r = 0.529, p = 0.001). 
The study also found an increased level of heparin 
sulfate was correlated to the severity of sepsis.31 
THE SHEDDING OF ENDOTHELIAL 
GLYCOCALYX
Various factors may cause the shedding of endo-
thelial glycocalyces, such as ischemic injury, reper-
fusion injury, and inflammation due to sepsis. It 
turned out that several factors can also cause shear-
ing of endothelial glycocalyx. Shedding causes the 
loss of some or complete function of glycocalyx, 
causing various endothelial and systemic problems. 
Atrial natriuretic peptide (ANP) is one of the causes 
of shedding. The ANP is known to increase vascular 
permeability. Bruegger et al. injected ANP into the 
lumen of the guinea pig coronary arteries, causing 
an increase in extravasation of hydroxyethyl starch 
(HES) 6% by 29%.34 
A study conducted by Chappell et  al. showed 
that in elective surgical patients with good cardio-
pulmonary conditions, after the administration of 
6% HES fluid loading was 20 ml/kg body weight, 
there was a significant increase in ANP, followed by 
an increase in shedding from syndecan-1, hyaluro-
nan in the blood, but not followed by an increase 
in heparin sulfate. Improved syndecan-1 is also 
detected in urine. This study also proved the release 
of ANP that occurs after fluid loading causes shed-
ding of endothelial glycocalyx. This study strength-
ens the role of ANP in glycocalyx shedding.35 
In patients who underwent Caesarean section 
with spinal anesthesia who received 750 ml bolus 
of crystalloid fluid, there was a significant increase 
from syndecan-1 and heparan sulfate but no signif-
icant increase in ANP levels. This is different from 
other studies, and it was probably due to the aver-
age bolus volume of 9 ml/kg of body weight, which 
is thought to not causing any significant stretches of 
the atrial wall to release ANP.36 
Acute hyperglycemia has been shown to cause 
shedding of endothelial glycocalyx especially hyal-
uronan, followed by increased vascular permea-
bility and plasma permeability. Hyperglycemia is 
a potent pro-oxidant and is a pro-inflammatory 
stimulus that is associated with shedding glycocalyx 
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through the radical oxygen pathway. Shedding 
glycocalyx is followed by increased procoagulant 
activity, as evidenced by increased coagulation of 
factor VIIa activity and stimulation of tissue factor. 
Endothelial glycocalyx is also the site of attachment 
of antithrombin III, so there is no doubt that the 
glycocalyx is followed by an increased coagulation 
activity.37 
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